Protara Therapeutics, Inc. (($TARA)) announced an update on their ongoing clinical study. Protara Therapeutics, Inc. is conducting a study titled ...

Enrollment in company’s first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached ...

As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating ...

The group of lifelong intestinal conditions known as inflammatory bowel disease (IBD), which includes Crohn's disease and ...